At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 113 enrolled
Drug / intervention
MK-3475drug
Likely dose
MK-3475 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins·interventional·Posted Jun 12, 2013·Updated Feb 6, 2020
In Brief
A Phase 2 clinical trial evaluating MK-3475 for MSI Positive Colorectal Cancer and 2 related conditions. Completed, enrolled 113 participants across 7 sites.
Detailed Summary
This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T cells) is effective (anti-tumor activity) and safe in three different patient populations. These include: 1. patients with MSI positive colon cancer, 2. patients with MSI negative colon cancer and 3. patients with other MSI positive cancers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMSI Positive Colorectal Cancer, MSI Negative Colorectal Cancer, MSI Positive Non-Colorectal Cancers
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartSep 2013
Primary CompletionAug 2019
TodayJul 2026
First PostedJun 12, 2013
Enrollment StartSep 1, 2013
Primary CompletionAug 1, 2019
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 13.1 years ago
Interventions
MK-3475drug
MK-3475 10 mg/kg every 14 days